Loading…
This event has ended. Visit the official site or create your own event on Sched.

View analytic
Monday, June 27 • 8:30am - 9:45am
#104: Impact of Biologics, Vaccines, Oncology, and Breakthrough Therapy Designation on Traditional Global Drug Development Strategy

Sign up or log in to save this to your schedule and see who's attending!

Limited Capacity seats available

Component Type: Forum
Level: Advanced
CE: ACPE 1.25 Knowledge UAN: 0286-0000-16-523-L01-P; CME 1.25; IACET 1.25; PDU 1.25 PMI 2166-000186; RN 1.25

This forum will provide an overview of traditional small molecule drug development, and highlight special considerations, opportunities, requirements, and risks for specialized programs, such as oncology, vaccines, biologics, or breakthrough therapies.

Learning Objectives

Explain how oncology, vaccine, and biologic drug development are similar to, or different from, a traditional small molecule program; Compare and contrast oncology, vaccine, and biologic drug development with respect to project leadership and project management strategies, approaches, and resource investment decisions; Discuss the impact of breakthrough therapy designation on each of these.

Chair

Eva M. Finney, PhD, PMP

Speaker

Panelist
Susan Uptain, PhD

Panelist
David Robinson, PhD



Chair
avatar for Eva Finney

Eva Finney

Director, Global Project & Alliance Management, Merck & Co., Inc.
Eva M. Finney, PhD, PMP, is Director, Global Project and Alliance Management at Merck & Co., Inc., where she has worked as a Project Manager for 13 years: 4 years in Molecular Profiling, supporting the Oncology and Neuroscience portfolios, & 9 years in GPAM, where she has managed multiple development programs from early to late stage, across a variety of therapeutic areas. Most recently, Eva has managed several NDA submissions leading to... Read More →

Speakers
DR

David Robinson

Principal Consultant, Robinson Vaccines and Biologics LLC
Independent consultant with 25 years experience in global vaccine and biologics product commercialization, process development and CMC regulatory strategy/execution (IND, BLA, PAS). Over 20 years at Merck, chaired the CMC development team that achieved approval of RotaTeq, an oral live virus vaccine, headed the product development teams that entered Merck’s first biosimilars into development and led the CMC regulatory group that achieved... Read More →
avatar for Susan Uptain

Susan Uptain

Head of Regulatory Affairs Operations, Shire
Dr. Susan Uptain is currently Head of Global Regulatory Operations at Baxalta, where she is responsible for operational excellence in execution of global regulatory strategy and tactics. Previously, she was Director of Project Management and Alliance Management at Merck & Co., Inc. Dr. Uptain has over 14 years’ experience in global drug development in Oncology, Diabetes and Respiratory. She holds a Ph.D. in Molecular and Cellular Biology from... Read More →


Monday June 27, 2016 8:30am - 9:45am
105AB Pennsylvania Convention Center 1101 Arch Street, Philadelphia, PA 19107 USA